• (PLX AI) – Pharma Mar says Sylentis, a subsidiary of Pharma Mar, initiates a new Phase III trial in the United States to evaluate the safety of tivanisiran in patients with dry eye disease.
  • • This Phase III study, called FYDES, will involve 26 hospitals in the United States
  • • It will evaluate the long-term safety of tivanisiran ophthalmic solution in patients with mild to severe dry eye disease
  • • The study has been authorized by the FDA and will be part of the New Drug Application

Quelle: PLX AI